The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

A method of preparing a Lilac Ginkgo Brick Tea includes the following steps: (1) mixing and drying fresh Lilac leaves and Ginkgo leaves to obtain a Lilac Ginkgo Tea; (2) fermenting the Lilac Ginkgo Tea to obtain a Fermented Lilac Ginkgo Tea; (3) mixing the Fermented Lilac Ginkgo Tea with a black tea to obtain a Fermented Lilac Ginkgo Tea Mixture; and (4) processing the Fermented Lilac Ginkgo Tea Mixture to obtain the Lilac Ginkgo Brick Tea.

A method of preparing a Lilac Ginkgo Brick Tea includes the following steps: (1) mixing and drying fresh Lilac leaves and Ginkgo leaves to obtain a Lilac Ginkgo Tea; (2) fermenting the Lilac Ginkgo Tea to obtain a Fermented Lilac Ginkgo Tea; (3) mixing the Fermented Lilac Ginkgo Tea with a black tea to obtain a Fermented Lilac Ginkgo Tea Mixture; and (4) processing the Fermented Lilac Ginkgo Tea Mixture to obtain the Lilac Ginkgo Brick Tea.

A method of preparing a Lilac Ginkgo Brick Tea includes the following steps: (1) mixing and drying fresh Lilac leaves and Ginkgo leaves to obtain a Lilac Ginkgo Tea; (2) fermenting the Lilac Ginkgo Tea to obtain a Fermented Lilac Ginkgo Tea; (3) mixing the Fermented Lilac Ginkgo Tea with a black tea to obtain a Fermented Lilac Ginkgo Tea Mixture; and (4) processing the Fermented Lilac Ginkgo Tea Mixture to obtain the Lilac Ginkgo Brick Tea.

Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

A protein-modified PLGA microsphere can be used to construct tissue-engineered nerve. The microspheres are loaded with active substances for treating peripheral nerve injury and are bound to tissue-engineered nerves. It has been shown that the prepared tissue-engineered nerve effectively promotes nerve regeneration after peripheral nerve injury.

Provided is a composition including a first phase comprising a first filler; a second phase, the second phase comprising a second filler; and a third phase comprising a third filler; and a fourth phase comprising a fourth filler; and a first active ingredient, wherein the first active ingredient is selected from the group consisting of caffeine, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna, black truffle, Syzygium aromaticum, Rosmarinus oficinalis, basil, oregano, lavender, true cinnamon, malabathrum, cananga odorata, Riboflavin, theanine, Ginkgo Biloba, Bacopa, Rhodiola Rosea, and combinations thereof.

Provided is a composition including a first phase comprising a first filler; a second phase, the second phase comprising a second filler; and a third phase comprising a third filler; and a fourth phase comprising a fourth filler; and a first active ingredient, wherein the first active ingredient is selected from the group consisting of caffeine, Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna, black truffle, Syzygium aromaticum, Rosmarinus oficinalis, basil, oregano, lavender, true cinnamon, malabathrum, cananga odorata, Riboflavin, theanine, Ginkgo Biloba, Bacopa, Rhodiola Rosea, and combinations thereof.

Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.